Associate Director, Risk Based Quality Management Lead

About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: The Associate Director , Risk-Based Quality Management (RBQM Lead) is accountable for the operational execution of RBQM activities across assigned clinical studies. Serving as the primary RBQM subject matter expert within study teams, this role implements and maintains study-level risk management, centralized monitoring, Key Risk Indicators (KRIs), Quality Tolerance Limits (QTLs), targeted monitoring strategies, and risk review processes. Working closely with Clinical Operations, Clinical Science, Data Management, Biostatistics, Medical Monitoring, and CRO partners, the RBQM Lead proactively identifies , evaluates, escalates, and mitigates risks throughout the clinical trial lifecycle to support participant safety, data reliability, and regulatory compliance. Role and Responsibilities: Study-Level RBQM Execution Serve as the RBQM Lead and core study team member from protocol development through study closeout Lead RBQM planning, execution, and ongoing risk oversight throughout study conduct. Develop and maintain study-specific RBQM Plans and Critical-to-Quality (CtQ) factors, ensuring alignment with protocol objectives and identified study risks. Risk Assessment & Risk Management Facilitate cross-functional risk identification and assessment workshops and lead creation and maintenance of study Risk Assessment and Categorization Tools (RACTs). Document, score, track, and periodically reassess risks, identifying new or emerging risks from study performance data and operational signals. Collaborate with study teams to implement risk mitigation strategies and actions, monitor their effectiveness, and recommend additional interventions when needed. Key Risk Indicator (KRI) Management Develop and maintain study-specific KRIs linked to identified risks and CtQ factors, including thresholds, triggers, and escalation pathways. Review and interpret KRI outputs and investigate threshold breaches and root causes. Facilitate study-team RBQM reviews and track KRI trends, actions, and mitigation outcomes. Q…